NasdaqGS:ALNYBiotechs
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After New Cardiovascular Partnership With Tenaya Therapeutics
Alnylam Pharmaceuticals (ALNY) just agreed to a research collaboration with Tenaya Therapeutics that centers on discovering up to 15 human genetic targets for potential cardiovascular drugs, supported by an upfront payment and sizeable milestone framework.
See our latest analysis for Alnylam Pharmaceuticals.
That Tenaya collaboration lands as Alnylam’s share price, now at $320.66, has seen a 30% decline over 90 days and a 19.9% year to date share price return, even though the 1 year total...